Table 1.
Baseline clinical and genetic characteristics of patients in the MyXI trial
| Characteristic | N | N = 556∗ |
|---|---|---|
| Age, y | 556 | 59 (54-64) |
| Male | 556 | 360 (65) |
| World Health Organization performance status | 534 | |
| 0 | 233 (44) | |
| 1 | 214 (40) | |
| 2 | 65 (12) | |
| ≥3 | 22 (4.1) | |
| Unknown | 22 | |
| International Staging System | 519 | |
| 1 | 167 (32) | |
| 2 | 240 (46) | |
| 3 | 112 (22) | |
| Unknown | 37 | |
| Revised International Staging System | 445 | |
| 1 | 78 (17) | |
| 2 | 314 (71) | |
| 3 | 53 (12) | |
| Unknown† | 111 | |
| Kappa light chain restriction | 553 | 363 (66) |
| Unknown | 3 | |
| Induction randomization | 556 | |
| KCRD | 122 (22) | |
| CTD | 210 (38) | |
| CRD | 224 (40) | |
| Maintenance randomization | 556 | |
| Len | 359 (65) | |
| Observation | 197 (35) | |
| t(4;14) | 556 | 76 (14) |
| t(14;16)/t(14;20) | 556 | 20 (3.6) |
| del(1p) | 556 | 56 (10) |
| del(17p) | 556 | 46 (8.3) |
| gain(1q) | 556 | 185 (33) |
CTD, cyclophosphamide, dexamethasone combined with thalidomide; CRD, cyclophosphamide, Len, and dexamethasone; KCRD, carfilzomib combined with CRD.
∗
Statistics presented: median (interquartile range) or n (%).
†
Main reason for missingness is missing lactate dehydrogenase test.